Author

F. Amary

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:chromatin & epigenetic regulation· 1 Assay:DNA methylation· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

A. M. Flanagan· 2 shared R. Tirabosco· 2 shared A. E. Grigoriadis· 1 shared A. Giess· 1 shared A. P. Leite· 1 shared A. Sosinky· 1 shared C. Davies· 1 shared F. Muyas· 1 shared

Activity by Year

2021-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

A. M. Flanagan

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Mechanisms underpinning osteosarcoma genome complexity and evolution

J. Espejo Valle-Inclan, S. De Noon, K. Trevers, H. Elrick, M. Tanguy, T. Butters, F. Muyas, F. Amary, R. Tirabosco, A. Giess, A. Sosinky, G. Elgar, A. M. Flanagan, I. Cortes-Ciriano

This study identifies chromothripsis and a novel LTA chromothripsis mechanism driving genome complexity and evolution in osteosarcoma, with prognostic implications for high-grade tumors.

bioRxiv · Dec 29, 2023 · PreprintCancer Biology

Aberrant paracrine signalling for bone remodelling underlies the mutant histone-driven giant cell tumour of bone.

L. Cottone, L. Ligammari, H. J. Knowles, H.-M. Lee, S. Henderson, S. Bianco, C. Davies, S. Strauss, F. Amary, A. P. Leite, R. Tirabosco, K. Haendler, J. L. Schultze, J. Herrero, P. ODonnell, , A. M. Flanagan

This study identifies aberrant paracrine signaling between osteoprogenitors and osteoclasts driven by H3.3 mutations as a mechanism underlying giant cell tumor of bone and its response to treatment.

bioRxiv · Dec 27, 2021Cancer Biology